- Home
- QUIK vs LPTX Comparison
QUIK vs LPTX Comparison
Compare QUIK & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QUIK
- LPTX
- Stock Information
- Founded
- QUIK 1988
- LPTX 2011
- Country
- QUIK United States
- LPTX United States
- Employees
- QUIK N/A
- LPTX N/A
- Industry
- QUIK Semiconductors
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QUIK Technology
- LPTX Health Care
- Exchange
- QUIK Nasdaq
- LPTX Nasdaq
- Market Cap
- QUIK 145.4M
- LPTX 119.6M
- IPO Year
- QUIK 1997
- LPTX N/A
- Fundamental
- Price
- QUIK $7.30
- LPTX $0.48
- Analyst Decision
- QUIK Strong Buy
- LPTX Buy
- Analyst Count
- QUIK 3
- LPTX 3
- Target Price
- QUIK $11.53
- LPTX $8.50
- AVG Volume (30 Days)
- QUIK 219.7K
- LPTX 1.5M
- Earning Date
- QUIK 02-25-2025
- LPTX 03-17-2025
- Dividend Yield
- QUIK N/A
- LPTX N/A
- EPS Growth
- QUIK N/A
- LPTX N/A
- EPS
- QUIK N/A
- LPTX N/A
- Revenue
- QUIK $21,886,000.00
- LPTX N/A
- Revenue This Year
- QUIK N/A
- LPTX N/A
- Revenue Next Year
- QUIK $27.52
- LPTX N/A
- P/E Ratio
- QUIK N/A
- LPTX N/A
- Revenue Growth
- QUIK 22.93
- LPTX N/A
- 52 Week Low
- QUIK $6.75
- LPTX $0.47
- 52 Week High
- QUIK $20.75
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- QUIK 41.42
- LPTX 19.00
- Support Level
- QUIK $6.75
- LPTX $0.47
- Resistance Level
- QUIK $8.61
- LPTX $0.53
- Average True Range (ATR)
- QUIK 0.59
- LPTX 0.04
- MACD
- QUIK 0.05
- LPTX 0.07
- Stochastic Oscillator
- QUIK 29.57
- LPTX 7.42
About QUIK QuickLogic Corporation
QuickLogic Corp provides programmable silicon and software platforms to enable its customers to develop custom hardware products in a fast time-to-market and cost-effective way. QuickLogic is a fabless semiconductor company with a product range: embedded FPGA (eFPGA) intellectual property (IP), low power, multi-core semiconductor system-on-chips (SoCs), discrete FPGAs, and AI software. The full range of platforms, software tools, and eFPGA IP enables the practical and efficient adoption of AI, voice, and sensor processing across Aerospace, and Defense, Consumer/Industrial IoT, and Consumer Electronics markets.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .